

German Acute Hepatitis B Study: a double-blind placebo-controlled randomised two-armed parallel-group phase IIb multi-centre trial

Submission date 10/01/2007	Recruitment status No longer recruiting	☐ Prospectively registered
Registration date 22/02/2007	Overall study status Completed	☐ Protocol
Last Edited 09/05/2019	Condition category Infections and Infestations	☐ Statistical analysis plan
		☒ Results
		☐ Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Hans Ludger Tillmann

Contact details
Universität Leipzig
Medizinische Klinik II
Philipp Rosenthal Str. 27
Leipzig
Germany
04103
+49 (0) 341 9712231
hans.tillmann@medizin.uni-leipzig.de

Additional identifiers

Clinical Trials Information System (CTIS)
2005-005987-94

Study information

Scientific Title

German Acute Hepatitis B Study: a double-blind placebo-controlled randomised two-armed parallel-group phase IIb multi-centre trial

Acronym

GAHB-Study

Study objectives

Early intervention with the antiviral drug lamivudine leads to earlier recovery from acute hepatitis B

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics committee of University Leipzig, approved on 29.11.2006, Bearbeitungs-Nr. 101-06 ff

Primary study design

Interventional

Study design

Double-blind placebo-controlled randomised two-armed parallel-group phase IIb multi-centre trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Acute Hepatitis B

Interventions

Administration of lamivudine versus placebo

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

Two primary endpoints are to be considered:

1. Time until Bilirubin < 2 mg/dl
2. Time to hospital discharge

They are ranked according to their relevance and reliability

Key secondary outcome(s)

The secondary endpoints are grouped into three categories according to their meaning:

1. Endpoints related to antiviral response:

- 1.1 Time to clear HBsAg (HBsAg negative)

- 1.2 In initially HBeAg positive patients: Time to clear HBeAg (HBeAg negative)

- 1.3 Rate of HBsAg positive patients at 6 and 12 months, respectively, after start of therapy

- 1.4 Time to first occurrence of anti-HBs
- 1.5 In initially HBeAg positive patients: Time to first occurrence of anti-HBe
- 1.6 Time to clear HBV-DNA (HBV-DNA below level of detection)
- 2. Endpoints related to liver function:
 - 2.1 Time to normalisation of prothrombin time (Quick $\geq 70\%$), if initially abnormal
 - 2.2 Time to normalisation of liver enzymes ALAT, ASAT (according to the appropriate reference levels of the central laboratory)
 - 2.3 Rate of patients progressing to fulminant hepatitis
- 3. Patient related endpoints:
 - 3.1 Rate of adverse and serious adverse events
 - 3.2 For patients with ongoing employment relationship: time to end of absence from work

Completion date

31/12/2009

Eligibility

Key inclusion criteria

- 1. Acute hepatitis
- 2. HBsAg positive
- 3. Compensated liver function (Quick $> 50\%$)
- 4. Bilirubin $> 5\text{mg/dl}$ (i.e. $> 85\mu\text{mol/l}$)
- 5. ALAT > 10 times upper normal range
- 6. Age ≥ 18 years
- 7. Hospitalization caused by acute hepatitis
- 8. Time since diagnosis < 8 days
- 9. Written informed consent of the patient

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 Years

Sex

Not Specified

Total final enrolment

35

Key exclusion criteria

1. Known or obvious pre-existing liver disease
2. Ongoing interferon therapy or stop of interferon less than 3 months ago
3. Ongoing drug abuse
4. HIV positive
5. Anti-HCV or HCV-RNA positive
6. Anti-HDV positive
7. Renal insufficiency (creatinine >1.5mg/dl or 135µmol/l)
8. Pregnant or nursing women
9. Women with child bearing potential (< 2 years after last menstruation) without effective contraception
10. Use of oral contraception
11. Patient with transplanted organs
12. Any disease requiring immunosuppressive therapy, incl. cancer chemotherapy
13. Any acute infectious disease requiring administration of sulphonamide/ trimethoprim
14. Evidence of any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug, or patient at high risk from treatment complications
15. Known hypersensitivity to any of the study drugs or its ingredients
16. Current or recent (within 30 days prior to start of trial treatment) treatment with another investigational drug or participation in another investigational trial
17. Expected low compliance (e.g. by travel distance to trial site)

Date of first enrolment

31/12/2006

Date of final enrolment

31/12/2009

Locations

Countries of recruitment

Germany

Study participating centre

Universität Leipzig

Leipzig

Germany

04103

Sponsor information

Organisation

University of Leipzig (Germany)

ROR

<https://ror.org/03s7gtk40>

Funder(s)

Funder type

Government

Funder Name

The GAHB-Study is funded by a grant of the Bundesministerium für Bildung und Forschung
Förderkennzeichen 01KG0507

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/10/2014	09/05/2019	Yes	No
Study website	Study website	11/11/2025	11/11/2025	No	Yes